SCHEMBL5147045

SCHEMBL5147045

CCCCCCOc1cc2ncccn2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
SOAT1 P35610 1/20 0.38
KDM4E B2RXH2 1/20 0.36
KDM4A O75164 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
TSHR P16473 2/20 0.35
NPC1 O15118 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
SMPD1 P17405 1/20 0.35
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
TLR8 Q9NR97 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872612 0.76 APOBEC3A (0.43) APOBEC3AAPOBEC3GKDM4CDRD2DRD4
SCHEMBL24983902 0.73 APOBEC3A (0.38) APOBEC3AAPOBEC3G
SCHEMBL21515669 0.69 APOBEC3A (0.49) APOBEC3AAPOBEC3G
Hydrochloric Acid SCHEMBL4800485 0.69 APOBEC3A (0.51) APOBEC3AAPOBEC3GKDM4ENPC1RAB9A
SCHEMBL5147052 0.68 CYP3A4 (0.45) CYP3A4CYP2D6SOAT1TSHRSMPD1
SCHEMBL7453009 0.67 SOAT1 (0.49) CYP3A4CYP2D6SOAT1KDM4ETSHR
SCHEMBL21494430 0.67 SOAT1 (0.49) CYP3A4CYP2D6SOAT1KDM4ETSHR
SCHEMBL4885285 0.67 SOAT1 (0.49) CYP3A4CYP2D6SOAT1KDM4ETSHR
SCHEMBL675902 0.67 SOAT1 (0.49) CYP3A4CYP2D6SOAT1KDM4ETSHR
SCHEMBL3221935 0.67 SOAT1 (0.49) CYP3A4CYP2D6SOAT1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed